Sitagliptin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 16: Line 16:
|drugClass=
|drugClass=


 
dipeptidyl peptidase-4 inhibitor


|indication=
|indication=


 
type 2 [[diabetes mellitus]]


|hasBlackBoxWarning=
|hasBlackBoxWarning=
Yes


|adverseReactions=
|adverseReactions=


 
[[hypoglycemia]], [[headache]], [[nasopharyngitis]], and [[upper respiratory infection]]


<!--Black Box Warning-->
<!--Black Box Warning-->

Revision as of 18:15, 29 July 2014

Sitagliptin
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Sitagliptin is a dipeptidyl peptidase-4 inhibitor that is FDA approved for the {{{indicationType}}} of type 2 diabetes mellitus. Common adverse reactions include hypoglycemia, headache, nasopharyngitis, and upper respiratory infection.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Sitagliptin in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sitagliptin in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Sitagliptin in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Sitagliptin in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sitagliptin in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Sitagliptin in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Sitagliptin in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sitagliptin in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Sitagliptin during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Sitagliptin with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Sitagliptin with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Sitagliptin with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Sitagliptin with respect to specific gender populations.

Race

There is no FDA guidance on the use of Sitagliptin with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Sitagliptin in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Sitagliptin in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Sitagliptin in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Sitagliptin in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Sitagliptin in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Sitagliptin in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Sitagliptin in the drug label.

Pharmacology

There is limited information regarding Sitagliptin Pharmacology in the drug label.

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Sitagliptin in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Sitagliptin in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Sitagliptin in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Sitagliptin in the drug label.

How Supplied

Storage

There is limited information regarding Sitagliptin Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Sitagliptin |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Sitagliptin |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Sitagliptin in the drug label.

Precautions with Alcohol

  • Alcohol-Sitagliptin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

  • Januvia® — Enjuvia®[2]
  • Januvia® — Jantoven®[2]
  • Januvia® — Janumet®[2]
  • sitaGLIPtin® — SUMAtriptan®[2]
  • sitaGLIPtin® — ZOLMitriptan®[2]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "JANUVIA (sitagliptin) tablet, film coated".
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Sitagliptin
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Sitagliptin
 |Label Name=Sitagliptin11.png

}}


{{#subobject: 

 |Label Page=Sitagliptin
 |Label Name=Sitagliptin11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Sitagliptin&oldid=1004250"